336 related articles for article (PubMed ID: 29310647)
1. Have dipeptidyl peptidase-4 inhibitors ameliorated the vascular complications of type 2 diabetes in large-scale trials? The potential confounding effect of stem-cell chemokines.
Packer M
Cardiovasc Diabetol; 2018 Jan; 17(1):9. PubMed ID: 29310647
[TBL] [Abstract][Full Text] [Related]
2. Stromal cell-derived factor-1 is upregulated by dipeptidyl peptidase-4 inhibition and has protective roles in progressive diabetic nephropathy.
Takashima S; Fujita H; Fujishima H; Shimizu T; Sato T; Morii T; Tsukiyama K; Narita T; Takahashi T; Drucker DJ; Seino Y; Yamada Y
Kidney Int; 2016 Oct; 90(4):783-96. PubMed ID: 27475229
[TBL] [Abstract][Full Text] [Related]
3. Cross-talk between the dipeptidyl peptidase-4 and stromal cell-derived factor-1 in stem cell homing and myocardial repair: Potential impact of dipeptidyl peptidase-4 inhibitors.
Anderluh M; Kocic G; Tomovic K; Kocic R; Deljanin-Ilic M; Smelcerovic A
Pharmacol Ther; 2016 Nov; 167():100-107. PubMed ID: 27484974
[TBL] [Abstract][Full Text] [Related]
4. Dipeptidyl peptidase-4 inhibition improves cardiac function in experimental myocardial infarction: Role of stromal cell-derived factor-1α.
Connelly KA; Advani A; Zhang Y; Advani SL; Kabir G; Abadeh A; Desjardins JF; Mitchell M; Thai K; Gilbert RE
J Diabetes; 2016 Jan; 8(1):63-75. PubMed ID: 25565455
[TBL] [Abstract][Full Text] [Related]
5. Risk of heart failure hospitalization among users of dipeptidyl peptidase-4 inhibitors compared to glucagon-like peptide-1 receptor agonists.
Dawwas GK; Smith SM; Park H
Cardiovasc Diabetol; 2018 Jul; 17(1):102. PubMed ID: 30016946
[TBL] [Abstract][Full Text] [Related]
6. The pleiotropic cardiovascular effects of dipeptidyl peptidase-4 inhibitors.
Avogaro A; Fadini GP
Br J Clin Pharmacol; 2018 Aug; 84(8):1686-1695. PubMed ID: 29667232
[TBL] [Abstract][Full Text] [Related]
7. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors.
Nauck MA; Meier JJ; Cavender MA; Abd El Aziz M; Drucker DJ
Circulation; 2017 Aug; 136(9):849-870. PubMed ID: 28847797
[TBL] [Abstract][Full Text] [Related]
8. The cardiovascular safety trials of DPP-4 inhibitors, GLP-1 agonists, and SGLT2 inhibitors.
Secrest MH; Udell JA; Filion KB
Trends Cardiovasc Med; 2017 Apr; 27(3):194-202. PubMed ID: 28291655
[TBL] [Abstract][Full Text] [Related]
9. Blood pressure-lowering effects of incretin-based diabetes therapies.
Lovshin JA; Zinman B
Can J Diabetes; 2014 Oct; 38(5):364-71. PubMed ID: 25284699
[TBL] [Abstract][Full Text] [Related]
10. Pleiotropic effects of glucagon-like peptide-1 (GLP-1)-based therapies on vascular complications in diabetes.
Yamagishi S; Matsui T
Curr Pharm Des; 2011 Dec; 17(38):4379-85. PubMed ID: 22204436
[TBL] [Abstract][Full Text] [Related]
11. Role of soluble and membrane-bound dipeptidyl peptidase-4 in diabetic nephropathy.
Hasan AA; Hocher B
J Mol Endocrinol; 2017 Jul; 59(1):R1-R10. PubMed ID: 28420715
[TBL] [Abstract][Full Text] [Related]
12. DPP-4 inhibitors in diabetic complications: role of DPP-4 beyond glucose control.
Bae EJ
Arch Pharm Res; 2016 Aug; 39(8):1114-28. PubMed ID: 27502601
[TBL] [Abstract][Full Text] [Related]
13. Dipeptidyl Peptidase 4 Inhibition Stimulates Distal Tubular Natriuresis and Increases in Circulating SDF-1α
Lovshin JA; Rajasekeran H; Lytvyn Y; Lovblom LE; Khan S; Alemu R; Locke A; Lai V; He H; Hittle L; Wang W; Drucker DJ; Cherney DZI
Diabetes Care; 2017 Aug; 40(8):1073-1081. PubMed ID: 28550195
[TBL] [Abstract][Full Text] [Related]
14. The effect of DPP-4 inhibition to improve functional outcome after stroke is mediated by the SDF-1α/CXCR4 pathway.
Chiazza F; Tammen H; Pintana H; Lietzau G; Collino M; Nyström T; Klein T; Darsalia V; Patrone C
Cardiovasc Diabetol; 2018 May; 17(1):60. PubMed ID: 29776406
[TBL] [Abstract][Full Text] [Related]
15. Impact of dipeptidyl-peptidase 4 inhibitors on cardiovascular diseases.
Xie W; Song X; Liu Z
Vascul Pharmacol; 2018 Oct; 109():17-26. PubMed ID: 29879463
[TBL] [Abstract][Full Text] [Related]
16. Cardiovascular effects of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes.
Koska J; Sands M; Burciu C; Reaven P
Diab Vasc Dis Res; 2015 May; 12(3):154-63. PubMed ID: 25852133
[TBL] [Abstract][Full Text] [Related]
17. Incretins: their physiology and application in the treatment of diabetes mellitus.
Tasyurek HM; Altunbas HA; Balci MK; Sanlioglu S
Diabetes Metab Res Rev; 2014 Jul; 30(5):354-71. PubMed ID: 24989141
[TBL] [Abstract][Full Text] [Related]
18. Pleiotropic mechanisms for the glucose-lowering action of DPP-4 inhibitors.
Omar B; Ahrén B
Diabetes; 2014 Jul; 63(7):2196-202. PubMed ID: 24962916
[TBL] [Abstract][Full Text] [Related]
19. Direct effects of DPP-4 inhibition on the vasculature. Reconciling basic evidence with lack of clinical evidence.
Fadini GP; Albiero M; Avogaro A
Vascul Pharmacol; 2015 Oct; 73():1-3. PubMed ID: 26254108
[TBL] [Abstract][Full Text] [Related]
20. Navigating the "MACE" in Cardiovascular Outcomes Trials and decoding the relevance of Atherosclerotic Cardiovascular Disease benefits versus Heart Failure benefits.
Hupfeld C; Mudaliar S
Diabetes Obes Metab; 2019 Aug; 21(8):1780-1789. PubMed ID: 30957945
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]